Platelet Monoamine Oxidase in Alzheimer's Disease

Smith, Robert C.; Ho, Beng T.; Kralik, Patricia M.; Vroulis, George; Gordon, Jack; Wolff, Judith

doi:10.1093/geronj/37.5.572

Cited by 24 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platelet MAO activity has been studied in several neuropsychiatric disorders (s. Bongioanni, 1987Bongioanni, , 1988. In Dementia of Alzheimer type (DAT), in accordance with the CNS data (Saura et al, 1994), a significantly higher platelet MAO activity was found (Adolfsson et al, 1980;Smith et al, 1982;Alexopoulos et al, 1984), as well as in Huntington's Chorea (Mann and Chiu, 1978) and in Amyotrophic Lateral Sclerosis (Belendiuk et al, 1981); in PD, Zeller et al (1976), but not Mann et al (1983), observed a qualitative difference in respect with controls.…”

Section: Introductionmentioning

confidence: 56%

Platelet phenolsulphotransferase activity, monoamine oxidase activity and peripheral-type benzodiazepine binding in demented patients

Bongioanni

Donato²,

Castagna

et al. 1996

J. Neural Transmission

View full text Add to dashboard Cite

Blood platelet phenolsulphotransferase and monoamine oxidase activities, as well as platelet peripheral-type benzodiazepine binding have been studied in several neuropsychiatric disorders, in order to identify biochemical markers for altered brain functioning. In the present work, we determined platelet phenolsulphotransferase and monoamine oxidase activities in demented patients: they showed significantly higher phenolsulphotransferase and monoamine oxidase activities than controls. A significant positive correlation was found between enzyme activities and severity of illness. In the same subjects, we evaluated platelet peripheral-type benzodiazepine binding: a significant reduction of Bmax values was observed in demented patients, whereas Kd values did not substantially differ between the two subject groups. These findings are discussed with reference to central nervous system biochemical abnormalities of demented subjects: it may be that in Dementia of Alzheimer type either some central biochemical changes are reflected in certain peripheral tissues (such as platelets), or a systemic derangement occurs together with a cerebral involvement.

show abstract

Section: Introductionmentioning

confidence: 56%

Platelet phenolsulphotransferase activity, monoamine oxidase activity and peripheral-type benzodiazepine binding in demented patients

Bongioanni

Donato²,

Castagna

et al. 1996

J. Neural Transmission

View full text Add to dashboard Cite

show abstract

“…Several previous studies reported increased activities of MAO-B in the brain and platelets of patients suffering from dementia [1][2][3][4][5][6][7][8][9][10][11]. The increase in brain MAO is due to transcriptional elevation of MAO-B protein [12] thus selective for MAO-B and predominant in plaque-associated astrocytes in neuropathologically verified Alzheimer's disease brains [13,14].…”

Section: Introductionmentioning

confidence: 99%

Platelet Monoamine Oxidase B Activity in Dementia

Götz

Fischer²,

Gsell³

et al. 1998

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Platelet monoamine oxidase B (MAO-B) activity has been found to increase significantly in demented patients. For the first time, a 4-year follow-up of platelet MAO-B activity and Mini-Mental State (MMS) was performed in patients with probable dementia of the Alzheimer type (DAT) and age-matched controls. MAO-B activity of DAT patients increased significantly 2 years after the beginning of the study as compared with controls and remained significantly higher for the entire period of the examinations (p < 0.0001). The decrease of the MMS scores did not correlate with the time course of the increase of platelet MAO-B activity (Spearman rank correlation test). The decline of the MMS scores of DAT patients preceded the elevation of MAO-B activity. Since degenerative processes in brain areas which are responsible for cognitive function and are reflected by the MMS scores rather affect cerebral cholinergic than monoaminergic neurotransmitter systems, degeneration of the latter at late stages of DAT might be reflected by increased platelet MAO-B activity.

show abstract

“…Studies have demonstrated an increase of MAO-B activity in the aging brain [1], This increase becomes more apparent in Alzheimer patients [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Monoamine Oxidase and Dementia: Treatment with an Inhibitor of MAO-B Activity

Agnoli

Martucci

Fabbrini

et al. 1990

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Patients suffering from Alzheimer type dementia have demonstrated an increase in MAO-B activity. Treatment of these patients with an inhibitor of the monoamine oxidase activity, such as L-Deprenyl (LD), might therefore provide a valid therapeutic intervention. The efficacy of LD was examined in a double-blind, drug versus placebo (PL) study on 20 patients diagnosed between stages 3 and 5 of primary degenerative dementia. Treatment duration was 90 days (5 mg twice a day). All patients underwent clinical, behavioral, and memory evaluations every 30 days. Subjects in the LD group demonstrated an improvement on both attention and memory measures; some of the changes were apparent after only 30 days of treatment. PL patients showed no such improvement and also evidenced a decrease in behavior efficiency during the experimental period. Two patients dropped out of the study, 1 from each treatment group. No differences were found in either the type and number of concomitant treatments or side effects between groups.

show abstract

Platelet Monoamine Oxidase in Alzheimer's Disease

Cited by 24 publications

References 0 publications

Platelet phenolsulphotransferase activity, monoamine oxidase activity and peripheral-type benzodiazepine binding in demented patients

Platelet phenolsulphotransferase activity, monoamine oxidase activity and peripheral-type benzodiazepine binding in demented patients

Platelet Monoamine Oxidase B Activity in Dementia

Monoamine Oxidase and Dementia: Treatment with an Inhibitor of MAO-B Activity

Contact Info

Product

Resources

About